Matching Items (1)
Description
As research progresses in the field of vaccinology, momentum has been gained to develop an efficacious and efficient dengue virus (DV) vaccine for all four serotypes. Dengue viral outbreaks across the world have called for a vaccine campaign. However, due to anti--"body dependent enhancement of infection, dengue virus has provided Researchers with challenges in developing a safe vaccine. Currently, there are a handful of vaccine candidates in clinical trial, but live chimeric attenuated vaccines dominate them. There are associated risks with using a live chimeric attenuated vaccine, but they are less expensive to generate and seem to provide a high immune response. Subunit vaccines are safer to use and can provide full protection for several years with then use of adjuvants and a booster shot. As a result, our lab is interested in pursuing this route to produce an effective dengue vaccine. The main target for a dengue subunit vaccine is the envelope protein, which is known to be an important recognition site by neutralizing antibodies. Therefore, expression of a recombinant envelope protein in a prokaryotic expression system is useful to study the immune response in vivo. This could be taken a step further and recombinant dengue envelope proteins can be expressed by a eukaryote to help generate hypotheses and insight to create a successful dengue virusn subunit vaccine.
ContributorsRiley, Jade (Author) / Reyes del Valle, Jorge (Thesis director) / Mason, Hugh (Committee member) / Katchman, Benjamin (Committee member) / Barrett, The Honors College (Contributor)
Created2013-05